新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » BIOON报道 » JAMA Neurol.:揭示多发性硬化症病人白介素IL-17F水平和干扰素β-1b疗法之间的关系

JAMA Neurol.:揭示多发性硬化症病人白介素IL-17F水平和干扰素β-1b疗法之间的关系

来源:生物谷 2013-06-06 23:58

2013年6月6日 讯 /生物谷BIOON/ --近日,刊登在国际杂志JAMA Neurol上的一篇研究报告中,来自海涅大学(Heinrich-Heine University)的研究者通过研究检测了在复发-缓解多发性硬化症病人中白细胞介素17F(IL-17F)及干扰素β-1b疗法效应之间的关系。

文中,研究者随机选择了239名进行干扰素β-1b疗法(250ug)至少两年的患者进行研究,研究者对其血清样本进行了免疫测定分析,测定了基准线和使用药物6个月后IL-17F的水平,并且对比了不同疾病人群的二者之间的差别:(1)低疾病活动病人和高疾病活动病人;(2)没有疾病活动的病人和有一些疾病活动的病人;(3)有反应的病人和无反应的病人。

研究结果显示,使用临床和磁共振成像(MRI)标准检测发现,在基准线和6个月后测定的IL-17F的水平和缺少对疗法的反应之间并无关联。疾病复发以及损伤与预处理血清中的IL-17F之间没有关联,当使用中和抗体的病人被排除在外时,结果并没有改变。

研究者表示,我们研究发现,血清中IL-17F的浓度并不能预测复发-缓解多发性硬化症病人干扰素β-1b疗法的效应,给予和疾病进展相关的多面性的病理生理学表现以及对疗法的反应,使用极端的病人群体结合基于免疫的生物标记物特性的方法或许是目前鉴别效应标记物的最为有效的方法。(生物谷Bioon.com)

Interleukin 17F Level and Interferon Beta Response in Patients With Multiple Sclerosis

Hans-Peter Hartung, MD; Lawrence Steinman, MD; Douglas S. Goodin, MD; Giancarlo Comi, MD; Stuart Cook, MD; Massimo Filippi, MD; Paul O’Connor, MD; Douglas R. Jeffery, MD; Ludwig Kappos, MD; Robert Axtell, MS, PhD; Volker Knappertz, MD; Timon Bogumil, MD; Susanne Schwenke, PhD; Ed Croze, PhD; Rupert Sandbrink, MD, PhD; Christopher Pohl, MD

Importance High serum levels of interleukin 17F (IL-17F) at baseline have been associated with suboptimal response to interferon beta in patients with relapsing-remitting multiple sclerosis. Objective To further investigate the role of IL-17F in predicting treatment response to interferon beta-1b in patients with relapsing-remitting multiple sclerosis using the Singulex Erenna IL-17F immunoassay. Design, Setting, and Patients Serum samples were analyzed from 239 randomly selected patients treated with interferon beta-1b, 250 μg, for at least 2 years in the Betaferon Efficacy Yielding Outcomes of a New Dose Study. Exposure Treatment with interferon beta-1b, 250 μg, for at least 2 years. Main Outcome Measures Levels of IL-17F at baseline and month 6 as well as the difference between the IL-17F levels at month 6 and baseline were compared between the following: (1) patients with less disease activity vs more disease activity; (2) patients with no disease activity vs some disease activity; and (3) responders vs nonresponders. Results Levels of IL-17F measured at baseline and month 6 did not correlate with lack of response to treatment after 2 years using clinical and magnetic resonance imaging criteria. Relapses and new lesions on magnetic resonance imaging were not associated with pretreatment serum IL-17F levels. When patients with neutralizing antibodies were excluded, the results did not change. All patients with levels of IL-17F greater than 200 pg/mL were associated with poor response with some clinical or radiological activity. Conclusions and Relevance An increase of IL-17F before and early after treatment with interferon beta-1b was not associated with poor response. These data do not support the value of IL-17F as a treatment response indicator for therapy of patients with multiple sclerosis with interferon beta, although high levels of IL-17F greater than 200 pg/mL may predict nonresponsiveness.

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库